Neuroinflammation has been implicated in Alzheimer’s disease onset and progression. Chronic neuroinflammation is initiated by amyloid-β-activated microglial cells that secrete immuno-modulatory molecules within the brain and into the vasculature. Inflammation is normally self-limiting and actively resolves by “switching off” the generation of pro-inflammatory mediators and by non-phlogistic clearance of spent cells and their debris to restore tissue homeostasis. Deficits in these anti-inflammatory/pro-resolution pathways may predispose to the development of chronic inflammation. The synthesis of endogenous lipid mediators from arachidonic acid, lipoxins via cyclooxygenase 2 and lipoxygenases, and conversion of exogenous polyunsaturated fatty acids, namely docosahexaenoic acid and eicosapentaenoic acid, to resolvins contributes to effective, timely resolution of acute inflammation. Work by Xiuzhe et al., 2020 in the Journal of Alzheimer’s Disease reported that plasma level of LXA4 is related to cognitive status in ischemic stroke patients suggesting that decreased LXA4 may be a potential risk factor for post post-stroke cognitive impairment. As evident by recent clinical trials and development of drug analogues, there is recent drive to search for lipoxin analogues as therapeutics for inflammatory diseases. Understanding how bioactive lipid signaling is involved in resolution will increase our understanding of controlling inflammation and may facilitate the discovery of new classes of therapeutic pro-resolution agents for evaluation in AD prevention studies.
KinneyJW, BemillerSM, MurtishawAS, LeisgangAM, SalazarAM, LambBT (2018) Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y)4, 575–590.
2.
FrostGR, JonasLA, LiY-M (2019) Friend, foe or both? Immune activity in Alzheimer’s disease. Front Aging Neurosci11, 337.
SerhanCN (2005) Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids73, 141–162.
8.
Bandeira-MeloC, BozzaPT, WellerPF (2002) The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol109, 393–400.
9.
LevyBD, SerhanCN (2014) Resolution and regulation of inflammation. In Pathobiology of Human Disease, McManus LM, Mitchell RN, eds. Academic Press, San Diego, pp. 332-348.
10.
BreitnerJC, GauBA, WelshKA, PlassmanBL, McDonaldWM, HelmsMJ, AnthonyJC (1994) Inverse association of anti-inflammatory treatments and Alzheimer’s disease: Initial results of a co-twin control study. Neurology44, 227–232.
11.
JordanF, QuinnTJ, McGuinnessB, PassmoreP, KellyJP, Tudur SmithC, MurphyK, DevaneD (2020) Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. Cochrane Database Syst Rev4, Cd011459.
12.
SzekelyCA, ThorneJE, ZandiPP, EkM, MessiasE, BreitnerJC, GoodmanSN (2004) Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: A systematic review. Neuroepidemiology23, 159–169.
13.
GelosaP, ColazzoF, TremoliE, SironiL, CastiglioniL (2017) Cysteinyl leukotrienes as potential pharmacological targets for cerebral diseases. Mediators Inflamm2017, 3454212–3454212.
14.
ImbimboBP, SolfrizziV, PanzaF (2010) Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment?. Front Aging Neurosci2, 19.
15.
WangX, MiaoZ, XuX, SchultzbergM, ZhaoY (2021) Reduced levels of plasma lipoxin A4 are associated with post-stroke cognitive impairment. J Alzheimers Dis79, 607–613.
16.
YuD, XuZ, YinX, ZhengF, LinX, PanQ, LiH (2015) Inverse relationship between serum lipoxin A4 level and the risk of metabolic syndrome in a middle-aged Chinese population. PloS One10, e0142848.
17.
GoicoecheaM, Sanchez-NiñoMD, OrtizA, García de VinuesaS, QuirogaB, BernisC, MoralesE, Fernández-JuarezG, de SequeraP, VerdallesU, VerdeE, LuñoJ (2017) Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins Leukot Essent Fatty Acids125, 8–13.
18.
FaridMahmoud, TahaHA, MohamedKhaled S., ElfikiMohamed A., FarhanHanan M., SolimanAyman S. (2019) The association between serum lipoxin A4 level and lupus nephritis. Med J Cairo U87, 3315–3324.
19.
HawkinsKE, DeMarsKM, AlexanderJC, de LeonLG, PachecoSC, GravesC, YangC, McCreaAO, FrankowskiJC, GarrettTJ, FeboM, Candelario-JalilE (2017) Targeting resolution of neuroinflammation after ischemic stroke with a lipoxin A4 analog: Protective mechanisms and long-term effects on neurological recovery. Brain Behav7, e00688.
20.
ZhuM, WangX, SunL, SchultzbergM, HjorthE (2018) Can inflammation be resolved in Alzheimer’s disease?. Ther Adv Neurol Disord11, 1756286418791107.
21.
SerhanCN, MaddoxJF, PetasisNA, Akritopoulou-ZanzeI, PapayianniA, BradyHR, ColganSP, MadaraJL (1995) Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry34, 14609–14615.
22.
GuilfordWJ, BaumanJG, SkuballaW, BauerS, WeiGP, DaveyD, SchaeferC, MallariC, TerkelsenJ, TsengJ-L, ShenJ, SubramanyamB, SchotteliusAJ, ParkinsonJF (2004) Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. J Med Chem47, 2157–2165.
